Meta-analysis of ciprofloxacin in treatment of crohn's disease

Biomedical Reports

Volumn 3, Issue 1, 2015, Pages 70-74

  Wu, Xiao Wei ^a   Ji, Hong Zan ^a   Wang, Fang Yu ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Ciprofloxacin; Crohn's disease; Meta analysis

Indexed keywords

CIPROFLOXACIN;

ANUS FISTULA; ARTICLE; CROHN DISEASE; DRUG EFFICACY; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84969418718     PISSN: 20499434     EISSN: 20499442     Source Type: Journal    
DOI: 10.3892/br.2014.368     Document Type: Article

References (30)

1. Baumgart DC and Sandborn WJ: Crohn's disease. Lancet 380: 1590-1605, 2012.
2. Cho JH and Brant SR: Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 140: 1704-1712, 2011.
3. Perencevich M and Burakoff R: Use of antibiotics in the treatment of inflammatory bowel disease. Inflamm Bowel Dis 12: 651-664, 2006.
4. Sartor RB: Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 126: 1620-1633, 2004.
5. Prantera C: What role do antibiotics have in the treatment of IBD? Nat Clin Pract Gastroenterol Hepatol 5: 670-671, 2008.
6. Dignass A, Van Assche G, Lindsay JO, et al; European Crohn's and Colitis Organisation (ECCO): The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis 4: 28-62, 2010.
7. Higgins JP, Altman DG, Gotzsche PC, et al; Cochrane Bias Methods Group; Cochrane Statistical Methods Group: The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343: d5928, 2011.
8. Higgins JP, Thompson SG, Deeks JJ and Altman DG: Measuring inconsistency in meta-analyses. BMJ 327: 557-560, 2003.
9. Egger M, Davey Smith G, Schneider M, et al: Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634, 1997.
10. Arnold GL, Beaves MR, Pryjdun VO and Mook WJ: Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis 8: 10-15, 2002.
11. Dewint P, Hansen BE, Verhey E, et al: Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut 63: 292-299, 2014.
12. Steinhart AH, Feagan BG, Wong CJ, et al: Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 123: 33-40, 2002.
13. Thia KT, Mahadevan U, Feagan BG, et al: Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 15: 17-24, 2009.
14. West RL, van der Woude CJ, Hansen BE, et al: Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther 20: 1329-1336, 2004.
15. Hammer HF: Gut microbiota and inflammatory bowel disease. Dig Dis 29: 550-553, 2011.
16. Chassaing B and Darfeuille-Michaud A: The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology 140: 1720-1728, 2011.
17. Prantera C and Scribano ML: Antibiotics and probiotics in inflammatory bowel disease: why, when, and how. Curr Opin Gastroenterol 25: 329-333, 2009.
18. Hooper DC and Wolfson JS: Fluoroquinolone antimicrobial agents. N Engl J Med 324: 384-394, 1991.
19. Sanders CC, Sanders WE Jr and Goering RV: Overview of preclinical studies with ciprofloxacin. Am J Med 82: 2-11, 1987.
20. Peppercorn MA: Is there a role for antibiotics as primary therapy in Crohn's ileitis? J Clin Gastroenterol 17: 235-237, 1993.
21. Prantera C, Berto E, Scribano ML and Falasco G: Use of antibiotics in the treatment of active Crohn's disease: experience with metronidazole and ciprofloxacin. Ital J Gastroenterol Hepatol 30: 602-606, 1998.
22. Greenbloom SL, Steinhart AH and Greenberg GR: Combination ciprofloxacin and metronidazole for active Crohn's disease. Can J Gastroenterol 12: 53-56, 1998.
23. Ishikawa T, Okamura S, Oshimoto H, Kobayashi R and Mori M: Metronidazole plus ciprofloxacin therapy for active Crohn's disease. Intern Med 42: 318-321, 2003.
24. Colombel JF, Lémann M, Cassagnou M, et al: A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol 94: 674-678, 1999.
25. Prantera C, Zannoni F, Scribano ML, et al: An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 91: 328-332, 1996.
26. Lapidus A, Bernell O, Hellers G and Lofberg R: Clinical course of colorectal Crohn's disease: a 35-year follow-up study of 507 patients. Gastroenterology 114: 1151-1160, 1998.
27. Schwartz DA, Pemberton JH and Sandborn WJ: Diagnosis and treatment of perianal fistulas in Crohn disease. Ann Intern Med 135: 906-918, 2001.
28. Wolf J: Ciprofloxacin may be useful in Crohn's disease. Gastroenterology 98 (abstract): A212, 1990.
29. Uza N, Nakase H, Ueno S, et al: The effect of medical treatment on patients with fistulizing Crohn's disease: a retrospective study. Intern Med 47: 193-199, 2008.
30. Turunen U, Farkkila M, Valtonen V, et al: Longterm outcome of ciprofloxacin treatment in severe perianal or fistulous Crohn's disease. Gastroenterology 104 (abstract): A793, 1993.